If the vaccine allowed, 15 million doses will immediately be distributed across the country, which would facilitate the return to normal in schools.
by
The panel responsible for advising the Food and Drug Administration (FDA), the US Medicines Agency advocated, Tuesday, October 26, to approve the vaccination of children aged 5 to 11 with the Pfizer- vaccine Biontech. The file is now on the FDA and the Center for Disease Control and Prevention Center
(CDC), which usually approve this kind of recommendation. This authorization, which could be complete on November 3, would pave the way for vaccination of 28 million children in the United States. These would receive a third of the dose administered more than 12 years, in two three-week injections.
Seventeen members of the committee voted in favor of the measure, one abstained. The vaccine, according to Pfizer, an effectiveness of 91% against a symptomatic COVID, the authorities felt that gains surpassed the risks. The main debate is the risk of myocarditis caused by the product. This inflammation of cardiac muscle is a side effect that has been detected in particular in adolescents and young adults. It caused 830 hospitalizations but no deaths in the United States, and no cases were detected in the clinical tests of Pfizer. Regarding COVID, more than 8,000 children in the 5-11 age group were hospitalized and a hundred died of COVID.
Promote the return to normal in schools
Once the vaccine is allowed, 15 million doses will be immediately distributed across the country, where vaccination, already available for more than 12 years, should facilitate the return to normal in schools. More than 2,000 institutions, welcoming more than a million students, were forced to close between August and October due to epidemics. According to Fiona Havers, CDC’s virologist, cited by the New York Times, the 5-11-year-old hospitalization rate is three times higher for black, Hispanic or Native American children than for white children.
Children from abroad will not need to be vaccinated to go to the United States from November 8th, when the prohibition of traveling for people living in 33 countries will be adjourned – including Those in Europe, China, Brazil and South Africa. Adults, they will have to have been protected against CVIV-19 by one of the vaccines recognized by the FDA and the World Health Organization. This measure therefore includes those who have received Chinese Vaccines from Sinopharm and Sinovac. It will have to have received two doses, including for a mixture of vaccines. On the other hand, the French choice to apply only one dose to the people who have contracted the disease is not considered sufficient.
You have 8.14% of this article to read. The rest is reserved for subscribers.